<SEC-DOCUMENT>0001062993-15-000482.txt : 20150204
<SEC-HEADER>0001062993-15-000482.hdr.sgml : 20150204
<ACCEPTANCE-DATETIME>20150204150245
ACCESSION NUMBER:		0001062993-15-000482
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150204
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150204
DATE AS OF CHANGE:		20150204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXARIA CORP.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		15575007

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 604 - 700 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1G8
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 604 - 700 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1G8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report </P>
<P align=center>Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=left colSpan=3>Date of Report (date of earliest event
    reported):&nbsp;&nbsp;&nbsp;&nbsp;February 2, 2015</TD></TR>
  <TR vAlign=bottom>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center colSpan=3><B>LEXARIA CORP.</B> <BR>(Exact name of
      registrant as specified in its charter) </TD></TR>
  <TR vAlign=top>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center>Nevada <BR>(State or other jurisdiction of
      <BR>incorporation) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="33%">000-52138 <BR>(Commission File Number)
      <BR></TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="33%">20-2000871 <BR>(IRS Employer
    Identification No.) <BR></TD></TR>
  <TR vAlign=top>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=left colSpan=2>&nbsp; &nbsp; &nbsp;#950 &#150; 1130 West Pender Street,
      Vancouver, British Columbia, Canada V6E 4A4 </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=left width="33%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=left colSpan=3>Registrant's telephone number, including area code:
      (604) 602-1675 </TD></TR>
  <TR vAlign=bottom>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center colSpan=3>(Former name or former address, if changed since
      last report.) </TD></TR></TABLE>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<P align=justify>[&nbsp; ]&nbsp; Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) </P>
<P align=justify>[&nbsp; ]&nbsp; Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 13e-4(c) under Exchange Act (17 CFR 240.13e -4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 7.01 Regulation FD Disclosure. </B></P>
<P align=justify>A copy of the news release announcing Lexaria announces it
maintains OTCQB marketplace status, filed as exhibit 99.1 to this current report and is hereby incorporated by
reference. </P>
<P align=justify><B>TEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left bgcolor="#EEEEEE"><a href="exhibit99-1.htm">99.1</a> </TD>
    <TD noWrap align=left width="92%" bgcolor="#EEEEEE">
    <a href="exhibit99-1.htm">News Release dated February 2, 2015</a> </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left colSpan=3>Dated: February 4, 2015</TD></TR>
  <TR>
    <TD colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=3>Lexaria Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;(Signature) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="5%">By: </TD>
    <TD align=right width="87%">
      <P align=justify><u>&#147;<I>/s/ Chris
      Bunka&#148;</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </u>
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="92%" colSpan=2>Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="92%" colSpan=2>President &amp; CEO
</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria, Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=3>Lexaria Maintains OTCQB Marketplace Status
</FONT></B></P>
<P align=justify>Kelowna, BC / February 2, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the &#147;Company&#148;) announces <FONT color=#222222>the Company has
submitted all the mandatory documents and has successfully met all of the
requirements for continued listing and trading on the OTCQB Marketplace. Partly
as a result of this, Realtime Level II Quote Display Service is now available to
investors free at </FONT><U><FONT
color=#0000ff>www.otcmarkets.com/stock/LXRP/quote </FONT></U></P>
<P align=justify>Lexaria is a US Company that trades in the USA on the OTCQB
venture stage marketplace for early stage and developing U.S. and international
companies. Companies listed at OTCQB are current in their reporting and undergo
an annual verification and management certification process. Lexaria has
continuously filed its quarterly and annual reports, and more, at the SEC
&#147;EDGAR&#148; site since 2006. </P>
<P align=justify>Since 2009, Lexaria also has traded on the Canadian Securities
Exchange in Canada, the fastest growing stock exchange in North America. Lexaria
is eligible for registered retirement accounts for Canadian investors, is
compliant with all CSE regulatory policies, and is Fully Reporting under
Canadian securities laws. </P>
<P align=justify>Lexaria is pleased to continue its open and transparent
communications and accessibility with its investors across North America and
expects this tradition to continue in 2015 and beyond. </P>
<P align=justify>About Lexaria <BR>Lexaria's shares are quoted in the USA with
symbol LXRP and in Canada with symbol LXX. The company searches for projects
that could provide potential above-market returns. www.lexarienergy.com </P>
<P align=justify>About ViPova<SUP>TM <BR></SUP>ViPova<SUP>TM </SUP>uses only
legal CBD oil extracts, grown from legal hemp in locations where it is legal to
do so, in ViPova<SUP>TM</SUP>-branded tea. ViPova<SUP>TM </SUP>uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPova<SUP>TM </SUP>has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:</P>
<P align=justify>Lexaria Corp. <BR>Chris Bunka <BR>Chairman &amp; CEO <BR>(250)
765-6424 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Current oil and gas production rates may not be sustainable and targeted
production rates may not occur. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements and filings.
There is no assurance that the medical marijuana, CBD sector, or alternative
health businesses will provide any benefit to Lexaria, or that the Company will
experience any growth through participation in these sectors. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will need to attempt to raise additional capital. There is no assurance that any
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. No statement herein has been evaluated by the Food
and Drug Administration (FDA). ViPova<SUP>TM</SUP> products are not intended to
diagnose, treat, cure or prevent any disease. </P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
